Mimoun Azzouz

Sheffield, ENG S102HQ, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Antisense Dipeptide Repeat Proteins Drive Widescale Purine Metabolism Aberration in C9orf72 Amyotrophic Lateral Sclerosis via ADA.

Antisense Dipeptide Repeat Proteins Drive Widescale Purine Metabolism Aberration in C9orf72 Amyotrophic Lateral Sclerosis via ADA.

Journal: International journal of molecular sciences

Published: January 25, 2026

Comparison of AAV9-driven motor neuron transduction following different CNS-directed delivery methods in mice.

Comparison of AAV9-driven motor neuron transduction following different CNS-directed delivery methods in mice.

Journal: Scientific reports

Published: November 14, 2025

Hypothesis-free evaluation of circulating metabolome provides cell-specific insights regarding the role of energy substrate availability in amyotrophic lateral sclerosis.

Hypothesis-free evaluation of circulating metabolome provides cell-specific insights regarding the role of energy substrate availability in amyotrophic lateral sclerosis.

Journal: BMC medicine

Published: October 08, 2025

The role of NOTCH3 in CADASIL pathogenesis: insights into novel therapies.

The role of NOTCH3 in CADASIL pathogenesis: insights into novel therapies.

Journal: Brain research

Published: April 17, 2025

Gene editing for collagen disorders: current advances and future perspectives.

Gene editing for collagen disorders: current advances and future perspectives.

Journal: Gene therapy

Published: April 05, 2025

Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products.

Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products.

Journal: Cell reports. Medicine

Published: February 17, 2025

Retraction Notice to: Corrigendum to "Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders".

Retraction Notice to: Corrigendum to "Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders".

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 12, 2024

Retraction Notice to: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.

Retraction Notice to: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 12, 2024

RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD.

RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD.

Journal: Life science alliance

Published: April 05, 2024

Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47.

Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47.

Journal: EMBO molecular medicine

Published: March 15, 2024

A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders.

A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: February 06, 2024

A cell-penetrant peptide blocking C9ORF72-repeat RNA nuclear export reduces the neurotoxic effects of dipeptide repeat proteins.

A cell-penetrant peptide blocking C9ORF72-repeat RNA nuclear export reduces the neurotoxic effects of dipeptide repeat proteins.

Journal: Science translational medicine

Published: March 01, 2023

Showing 1-12 of 60

Last Updated: 09/26/2026